Considering translation to clinical practice, a very short time-window of minutes/few hours would be available for A2A receptor antagonists after stroke, while a focus on inflammatory responses to stroke provides a wide therapeutic time-window of hours and even days after stroke for adenosine A2A receptor agonists. The gene discussed is ADORA2A; the disease is Stroke.